ES2571929T3 - Procedimiento para determinar la cantidad de CD36 circulante - Google Patents

Procedimiento para determinar la cantidad de CD36 circulante

Info

Publication number
ES2571929T3
ES2571929T3 ES05744476T ES05744476T ES2571929T3 ES 2571929 T3 ES2571929 T3 ES 2571929T3 ES 05744476 T ES05744476 T ES 05744476T ES 05744476 T ES05744476 T ES 05744476T ES 2571929 T3 ES2571929 T3 ES 2571929T3
Authority
ES
Spain
Prior art keywords
amount
antibody
circulating
procedure
investigated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05744476T
Other languages
English (en)
Inventor
Aase Handberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Region Nordjylland
Original Assignee
Region Nordjylland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Region Nordjylland filed Critical Region Nordjylland
Priority claimed from PCT/DK2005/000352 external-priority patent/WO2005116644A2/en
Application granted granted Critical
Publication of ES2571929T3 publication Critical patent/ES2571929T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G01N33/54386—Analytical elements
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Un procedimiento para determinar la cantidad de proteína CD36 circulante o una fracción de la misma que está presente en una fracción de plasma de elevado peso molecular libre de células, utilizando un procedimiento inmunológico que comprende las etapas de: (i) proporcionar una muestra de plasma que ha de ser investigada, (ii) degradar complejos de elevado peso molecular en dicha muestra de plasma, (iii) proporcionar un anticuerpo anti-CD36, (iv) exponer la muestra que ha de ser investigada al anticuerpo, y (v) detectar y cuantificar la cantidad del anticuerpo que se une a CD36.
ES05744476T 2004-05-26 2005-05-26 Procedimiento para determinar la cantidad de CD36 circulante Expired - Lifetime ES2571929T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200400829 2004-05-26
US60112304P 2004-08-13 2004-08-13
DKPA200401222 2004-08-13
PCT/DK2005/000352 WO2005116644A2 (en) 2004-05-26 2005-05-26 Method of evaluation of the relative risk of developing atherosclerosis in patients

Publications (1)

Publication Number Publication Date
ES2571929T3 true ES2571929T3 (es) 2016-05-27

Family

ID=40011253

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05744476T Expired - Lifetime ES2571929T3 (es) 2004-05-26 2005-05-26 Procedimiento para determinar la cantidad de CD36 circulante

Country Status (2)

Country Link
US (2) US9372190B2 (es)
ES (1) ES2571929T3 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2344890B1 (en) * 2008-10-20 2021-08-11 Liposcience, Inc. Lipoprotein insulin resistance indexes and related methods
WO2011061749A2 (en) * 2009-11-19 2011-05-26 Ganga Raju Gokaraju Agents derived from holoptelea integrifolia and their compositions for the control of metabolic syndrome and associated diseases
US20130149386A1 (en) * 2011-12-07 2013-06-13 Region Nordjylland Cd36 as biomarker for steatosis
EP3485265B1 (en) 2016-07-12 2025-03-12 Ascensia Diabetes Care Holdings AG Method for electrochemical analysis by use of alternating output signals from two electrodes
JP7074753B2 (ja) * 2016-12-05 2022-05-24 アセンシア・ダイアベティス・ケア・ホールディングス・アーゲー リスク因子モニタリング

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9306053D0 (en) * 1993-03-24 1993-05-12 Nycomed Pharma As Method and assay
ES2239801T3 (es) * 1997-04-02 2005-10-01 The Brigham And Women's Hospital, Inc. Uso de un agente para disminuir el riesgo de enfermedad cardiovascular.
US6322976B1 (en) 1998-05-28 2001-11-27 Medical Research Council Compositions and methods of disease diagnosis and therapy
JP2000180447A (ja) 1998-12-11 2000-06-30 Dainippon Pharmaceut Co Ltd 急性心筋梗塞の判定方法及び判定用試薬
JP2001056338A (ja) 1999-08-19 2001-02-27 Tokyoto Igaku Kenkyu Kiko 経皮的冠動脈形成術後の冠動脈再狭窄の可能性を検出する方法
GB9927502D0 (en) 1999-11-19 2000-01-19 Isis Innovation CD36 Polymorphisms
US6812023B1 (en) * 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
WO2004017986A1 (en) 2002-08-23 2004-03-04 Valorisation-Recherche, Societe En Commandite Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
US20040076621A1 (en) * 2002-10-16 2004-04-22 Isis Pharmaceuticals Inc. Antisense modulation of CD36 expression

Also Published As

Publication number Publication date
US9372190B2 (en) 2016-06-21
US20080280376A1 (en) 2008-11-13
US20160370365A1 (en) 2016-12-22

Similar Documents

Publication Publication Date Title
Xu et al. Serum protein S100A9, SOD3, and MMP9 as new diagnostic biomarkers for pulmonary tuberculosis by iTRAQ‐coupled two‐dimensional LC‐MS/MS
Tsuchida et al. Application of quantitative proteomic analysis using tandem mass tags for discovery and identification of novel biomarkers in periodontal disease
BR112012031071A2 (pt) 8-proteínas de ligação à il-1
HN2008001104A (es) Compuestos para anticuerpos de dickpf-1 y70-4
Corona et al. Metabolomics biomarkers of frailty in elderly breast cancer patients
BRPI0812875A2 (pt) " método pra identificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, anticorpo específico para proteína ligante de heparina, método pra reduzir o risco de um indivíduo desenvolver sépsis severa, e, kit de teste ".
BRPI0923199B8 (pt) método para determinar a presença de anticorpos de fixação de complemento
NZ628463A (en) Ratio based biomarkers and methods for use thereof
BR112012008665A2 (pt) tratamento de câncer
BRPI1013688A8 (pt) Proteínas de ligação de il-17.
AR065150A1 (es) Metodos y dispositivos para el diagnostico de apendicitis
BR112016004320A2 (pt) biossensor, sistema, kit, métodos de determinação ou de identificação e de quantificação de uma concentração de amônia ou íon amônio, de diagnóstico de uma doença metabólica em um sujeito, de determinação da resposta do paciente a uma terapia, de fabricação de um biossensor, de um sistema ou de qualquer tira de teste e de detecção da presença, ausência, ou quantidade de aminoácidos em uma amostra, e, tira de teste
AR070168A1 (es) Anticuerpos anti-cd79b e inmunoconjugados y metodos de uso de los mismos
PE20131062A1 (es) Uso de hmgb1 como marcador biologico de afecciones intestinales inflamatorias, metodo no invasivo para su deteccion en muestras fecales y kit para su realizacion
CO6280567A2 (es) Establecimiento de un anticuerpo monoclonal para detector de proteinas pag en la circulacion
BRPI0820177B8 (pt) métodos para produzir um extrato de proteína a partir de células fixadas ou não-fixadas
WO2009023331A3 (en) Antibodies and improved test sample handling methods for use in assays for myeloperoxidase
DK1915626T3 (da) Apoptosesensitivitet mod Apo2L/TRAIL ved testning for GalNac-T14-ekspression i celler/væv
AR053948A1 (es) Deteccion de un antigeno diana independientemente de la presencia o ausencia de un anticuerpo terapeutico correspondiente
EA200702361A1 (ru) АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
Penmetsa et al. Analysis of plasma homocysteine levels in patients with chronic periodontitis before and after nonsurgical periodontal therapy using high-performance liquid chromatography
BR112013033478A2 (pt) método para determinar a função de reparo de malparemento
Hsu et al. Downregulation of the antioxidant protein peroxiredoxin 2 contributes to angiotensin II–mediated podocyte apoptosis
ES2571929T3 (es) Procedimiento para determinar la cantidad de CD36 circulante
DE602006010242D1 (de) Immunoassay mit doppelter standardkurve